CenturyLink Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

CenturyLink Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-1,540	Closed	-$124K	–	270
2015 Q3	$124K	Buy	1,540 +438	+40%	+$48.7K	0.04%	233
2015 Q2	$132K	Buy	1,102 +1,039	+1,649%	+$124K	0.04%	245
2015 Q1	$7K	Buy	+63	New	+$6.38K	﹤0.01%	280
2014 Q3	–	Sell	-949	Closed	-$60K	–	247
2014 Q2	$60K	Buy	949 +261	+38%	+$15.5K	0.02%	250
2014 Q1	$46K	Buy	+688	New	+$53.3K	0.01%	256

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

CenturyLink Investment Management's ALNY Position: Q4 2015 in Review

CenturyLink Investment Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2015, closing a stake of 1,540 shares — an estimated $124K sold.

CenturyLink Investment Management first reported a position in ALNY in Q1 2014 and held it in 5 quarters. The position peaked at $132K in Q2 2015. 260 funds tracked by Wall St. Rank hold ALNY as of Q4 2015.

CenturyLink Investment Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
CenturyLink Investment Management sold 1,540 Alnylam Pharmaceuticals shares in Q4 2015, an estimated $124K.
CenturyLink Investment Management first reported a position in Alnylam Pharmaceuticals in Q1 2014 and held it in 5 quarters.
CenturyLink Investment Management's Alnylam Pharmaceuticals position peaked at $132K in Q2 2015.
260 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2015.

Based on CenturyLink Investment Management's 13F filing for Q4 2015, filed 25 Jan 2016.